Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiopulmonary Resuscitation III: AED Use

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The present and the future of risk stratification for and prevention of sudden cardiac death: A Heart Rhythm Society think tank meeting.

Heart rhythm·2026

Same author

Physiologic Pacing in Heart Failure. Reply.

The New England journal of medicine·2026

Same author

HRS position statement: Changing the tide in CPR and AED education for students in the United States.

Heart rhythm·2026

Same author

State of the Journal 2026.

Heart rhythm O2·2026

Same author

Physiologic Pacing in Heart Failure.

The New England journal of medicine·2026

Same author

Presenting the abstracts from CardioRhythm Congress 2025.

Heart rhythm O2·2025

Search research articles

Related Experiment Video

Updated: Jul 20, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

New indications for implantable defibrillator therapy.

Jeanne E Poole¹,

¹University of Washington School of Medicine,Division of Cardiology, Box 356422, 1959 NE Pacific Street, Seattle, WA 98195-6422, USA. jpoole@u.washington.edu

Current Cardiology Reports

|September 8, 2006

Summary

Implantable cardioverter defibrillator (ICD) therapy reduces mortality in heart failure patients. This therapy is now indicated for patients with or without coronary artery disease, expanding its use for sudden cardiac death prevention.

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Related Experiment Videos

Last Updated: Jul 20, 2026

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

A New Single Chamber Implantable Defibrillator with Atrial Sensing: A Practical Demonstration of Sensing and Ease of Implantation

Published on: February 28, 2012

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

Area of Science:

Cardiology
Medical Devices
Clinical Trials

Background:

Implantable cardioverter defibrillator (ICD) therapy is a recognized treatment for patients at high risk of sudden cardiac death.
Previous trials have demonstrated the efficacy of ICDs in patients with coronary artery disease and reduced left ventricular systolic function.

Purpose of the Study:

To evaluate the effectiveness of ICD therapy in patients with moderate heart failure symptoms, regardless of the cause (ischemic or nonischemic).
To determine if ICD therapy offers mortality benefits beyond conventional medical treatment in this patient population.

Main Methods:

The study involved patients with moderate heart failure symptoms.
A comparison was made between patients receiving ICD therapy and those receiving conventional medical therapy.
The Sudden Cardiac Death in Heart Failure Trial (SCD-HF) data was analyzed.

Main Results:

Patients with moderate heart failure symptoms receiving ICD therapy showed reduced mortality compared to those on conventional medical therapy alone.
The benefits of ICD therapy were observed in both ischemic and nonischemic heart failure causes.
The findings confirm earlier trial results and broaden the indications for ICD use.

Conclusions:

Implantable cardioverter defibrillator (ICD) therapy is effective in reducing mortality in patients with moderate heart failure symptoms.
ICD therapy is now indicated for a wider range of patients, including those without coronary artery disease.
The study reinforces the role of ICDs in preventing sudden cardiac death in heart failure patients.